{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:37Z","timestamp":1790899237996,"version":"4.1.0"},"reference-count":30,"publisher":"National Center for Global Health and Medicine (JST)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["GHM"],"published-print":{"date-parts":[[2025,10,31]]},"DOI":"10.35772\/ghm.2025.01102","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T22:08:31Z","timestamp":1759442911000},"page":"347-351","source":"Crossref","is-referenced-by-count":3,"title":["Perioperative and precision strategies in resectable intrahepatic cholangiocarcinoma"],"prefix":"10.35772","volume":"7","author":[{"given":"Lu","family":"Chen","sequence":"first","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"Department of Hepatobiliary Cancer, Liver Cancer Research Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyu","family":"Han","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"Department of Hepatobiliary Cancer, Liver Cancer Research Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqiang","family":"Song","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"Department of Hepatobiliary Cancer, Liver Cancer Research Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Song","sequence":"additional","affiliation":[{"name":"Center for Clinical Sciences, Japan institute for Health Security, Tokyo, Japan."},{"name":"National College of Nursing, Japan Institute for Health Security, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[{"name":"National College of Nursing, Japan Institute for Health Security, Tokyo, Japan."},{"name":"National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21485","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209-249.","DOI":"10.3322\/caac.21660"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hucke F, Pinter M, Hucke M, Bota S, Bolf D, Hackl M, Peck-Radosavljevic M. Changing epidemiological trends of hepatobiliary carcinomas in Austria 2010\u20132018. Cancers (Basel). 2022; 14:3093.","DOI":"10.3390\/cancers14133093"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Endo I, Gonen M, Yopp AC, <i>et al<\/i>. Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008; 248:84-96.","DOI":"10.1097\/SLA.0b013e318176c4d3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Franchi E, Donadon M, Torzilli G. Effects of volume on outcome in hepatobiliary surgery: A review with guidelines proposal. Glob Health Med. 2020; 2:292-297.","DOI":"10.35772\/ghm.2020.01013"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: The AJCC\/UICC 8th edition updates. Chin Clin Oncol. 2018; 7:52.","DOI":"10.21037\/cco.2018.07.03"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Huang L, Li J, Zhu S, Wang L, Li G, Pan J, Zhang C, Lai J, Tian Y, Chen S. Machine learning-based prognostic prediction and surgical guidance for intrahepatic cholangiocarcinoma. Biosci Trends. 2025; 18:545-554.","DOI":"10.5582\/bst.2024.01312"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Li J, Moustafa M, Linecker M, <i>et al<\/i>. ALPPS for locally advanced intrahepatic cholangiocarcinoma: Did aggressive surgery lead to the oncological benefit? An international multi-center study. Ann Surg Oncol. 2020; 27:1372-1384.","DOI":"10.1245\/s10434-020-08274-3"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mi S, Qiu G, Zhang Z, Jin Z, Xie Q, Hou Z, Ji J, Huang J. Development and validation of a machine-learning model to predict lymph node metastasis of intrahepatic cholangiocarcinoma: A retrospective cohort study. Biosci Trends. 2025; 18:535-544.","DOI":"10.5582\/bst.2024.01282"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick RD, Choti MA, Pawlik TM. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009; 16:14-22.","DOI":"10.1245\/s10434-008-0180-z"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. European Association for the Study of the Liver. EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023; 79:181-208.","DOI":"10.1016\/j.jhep.2023.09.006"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kobayashi K, Uldry E, Demartines N, Halkic N. Liver resections between 2014 and 2020 in the Lausanne University Hospital, Switzerland. Glob Health Med. 2020; 2:337-342.","DOI":"10.35772\/ghm.2020.01059"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Primrose JN, Fox RP, Palmer DH, <i>et al<\/i>. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019; 20:663-673.","DOI":"10.1016\/S1470-2045(18)30915-X"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nakachi K, Ikeda M, Konishi M, <i>et al<\/i>. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): A multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023; 401:195-203.","DOI":"10.1016\/S0140-6736(22)02038-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Edeline J, Benabdelghani M, Bertaut A, <i>et al<\/i>. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A randomized phase III study. J Clin Oncol. 2019; 37:658-667.","DOI":"10.1200\/JCO.18.00050"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Zheng X, Chen B, Wu JX, Jia AY, Rong WQ, Wang LM, Wu F, Zhao YT, Li YX, Wang WH. Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic cholangiocarcinoma that adhere to major vessels. Cancer Manag Res. 2018; 10:3973-3981.","DOI":"10.2147\/CMAR.S172940"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Li T, Qin LX, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L, Tang ZY, Fan J. Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection. Liver Int. 2014; 34:953-960.","DOI":"10.1111\/liv.12364"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Li J, Wang Q, Lei Z, Wu D, Si A, Wang K, Wan X, Wang Y, Yan Z, Xia Y, Lau WY, Wu M, Shen F. Adjuvant transarterial chemoembolization following liver resection for intrahepatic cholangiocarcinoma based on survival risk stratification. Oncologist. 2015; 20:640-647.","DOI":"10.1634\/theoncologist.2014-0470"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yadav S, Xie H, Bin-Riaz I, Sharma P, Durani U, Goyal G, Borah B, Borad MJ, Smoot RL, Roberts LR, Go RS, McWilliams RR, Mahipal A. Neoadjuvant <i>vs<\/i>. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Eur J Surg Oncol. 2019; 45:1432-1438.","DOI":"10.1016\/j.ejso.2019.03.023"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sumiyoshi T, Shima Y, Okabayashi T, Negoro Y, Shimada Y, Iwata J, Matsumoto M, Hata Y, Noda Y, Sui K, Sueda T. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma. World J Surg. 2018; 42:2910-2918.","DOI":"10.1007\/s00268-018-4558-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Konstantinidis IT, Groot Koerkamp B, Do RK, G\u00f6nen M, Fong Y, Allen PJ, D&apos;Angelica MI, Kingham TP, DeMatteo RP, Klimstra DS, Kemeny NE, Jarnagin WR. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016; 122:758-765.","DOI":"10.1002\/cncr.29824"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Rayar M, Sulpice L, Edeline J, Garin E, Levi Sandri GB, Meunier B, Boucher E, Boudjema K. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol. 2015; 22:3102-3108.","DOI":"10.1245\/s10434-014-4365-3"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ross JS, Wang K, Gay L, <i>et al<\/i>. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014; 19:235-242.","DOI":"10.1634\/theoncologist.2013-0352"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Javle M, Bekaii-Saab T, Jain A, <i>et al<\/i>. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016; 122:3838-3847.","DOI":"10.1002\/cncr.30254"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Abou-Alfa GK, Sahai V, Hollebecque A, <i>et al<\/i>. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol. 2020; 21:671-684.","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Abou-Alfa GK, Macarulla T, Javle MM, <i>et al<\/i>. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21:796-807.","DOI":"10.1016\/S1470-2045(20)30157-1"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Bouffet E, Geoerger B, Moertel C, Whitlock JA, Aerts I, Hargrave D, Osterloh L, Tan E, Choi J, Russo M, Fox E. Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma. J Clin Oncol. 2023; 41:664-674.","DOI":"10.1200\/JCO.22.01000"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Le DT, Durham JN, Smith KN, <i>et al<\/i>. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357:409-413.","DOI":"10.1126\/science.aan6733"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Zhu M, Jin M, Zhao X, Shen S, Chen Y, Xiao H, Wei G, He Q, Li B, Peng Z. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma. BMC Med. 2024; 22:165.","DOI":"10.1186\/s12916-024-03381-4"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Chao J, Wang S, Wang H, <i>et al<\/i>. Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: Effectiveness, safety, and biomarker analysis. Cancer Immunol Immunother. 2023; 72:3717-3726.","DOI":"10.1007\/s00262-023-03523-2"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Yang J, Gong Y, Lam VK, <i>et al<\/i>. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis. 2020; 11:346.","DOI":"10.1038\/s41419-020-2531-z"}],"container-title":["Global Health &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/7\/5\/7_2025.01102\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T03:58:45Z","timestamp":1763179125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/7\/5\/7_2025.01102\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.35772\/ghm.2025.01102","relation":{},"ISSN":["2434-9186","2434-9194"],"issn-type":[{"value":"2434-9186","type":"print"},{"value":"2434-9194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"2025.01102"}}